Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US
Delivers Global First With Ranibizumab Biosimilar Launch Through Partner Biogen
Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.
You may also be interested in...
Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.
Samsung Bioepis has taken a further step towards registering its SB12 eculizumab biosimilar after its filing for the Soliris rival was accepted for review by the European Medicines Agency.